Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2026-05-12 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
辰欣药业股份有限公司关于参加2026年山东辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 75% confidence The document is a corporate announcement that the company will participate in an online investor reception day event. It does not contain financial statements, a presentation deck, voting results, or management changes—it simply informs investors of an upcoming event. This does not fit into any specific report category (e.g., ER, IR, IP) and is a general regulatory announcement. Therefore, it falls under the fallback category: Regulatory Filings (RNS).
2026-05-12 Chinese
辰欣药业股份有限公司2025年年度股东会决议公告
Regulatory Filings
2026-05-07 Chinese
山东国曜琴岛（济南）律师事务所关于辰欣药业股份有限公司2025年年度股东会的法律意见书
Regulatory Filings
2026-05-07 Chinese
辰欣药业股份有限公司董事会关于独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board of directors regarding the independence self-assessment of independent directors for the year 2025. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The content focuses on governance compliance and the independence of board members, which aligns with governance-related disclosures. The document is short (528 characters) and is a specific report on board governance matters, not an announcement or a general regulatory filing. Therefore, it fits best under Governance Information (CGR).
2026-04-02 Chinese
辰欣药业股份有限公司2025年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled '2025 年度董事会审计委员会履职情况报告' which translates to '2025 Annual Report on the Board Audit Committee's Performance'. It details the activities, meetings, and evaluations conducted by the audit committee during the 2025 fiscal year. The content includes oversight of external auditors, internal audit work, financial report reviews, and internal control evaluations. It is a detailed report on the audit committee's duties and performance rather than a standalone audit report or a full annual report. The document is about the audit committee's work and their supervisory role, which fits the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a Management Report (MDA). The length is 4069 characters, which is sufficient for a substantive report. Therefore, the best classification is AR (Audit Report / Information).
2026-04-02 Chinese
辰欣药业股份有限公司2025年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2025 年度董事会工作报告' which translates to '2025 Annual Board of Directors Work Report'. It details the activities, meetings, governance, and plans of the company's board of directors for the year 2025. It includes descriptions of board meetings, shareholder meetings, committee activities, independent directors' roles, governance improvements, and future plans. The content is focused on the board's work and governance rather than financial statements or audit results. It is a comprehensive report on board and management activities rather than a financial report or announcement. Therefore, the document fits best under the category 'Board/Management Information (MANG)', which covers announcements of changes or reports related to the company's board or senior management activities.
2026-04-02 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.